Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion： a retrospective analysis of prognostic factors in China

作     者：Heng Li Wenjie Xiong Huimin Liu Shuhua Yi Zhen Yu Wei Liu Rui Lyu Tingyu Wang Dehui Zou Zengjun Li Lugui Qiu 

作者机构：State Key Laboratory of Experimental Hematology Institute of Hematology and Blood Disease Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300020 China 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2017年第29卷第2期

页      面：156-165页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from the National Nature Science Foundation of China (No. 81200395, 81370632) the National Science and Technology supporting Program (No. 2014BAI09B12) the Fundamental Application and Advanced Technology Research Program of Tianjin (No. 15JCYBJC27900) the National Public Health Grand Research Foundation (No. 201202017) 

主　　题：17p deletion chronic lymphocytic leukemia （CLL） fluorescent in situ hybridization （FISH） del 17pin CLL 

摘      要：Objective： This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia （CLL） and a 17p deletion （17p-） and identify the predictive factors within this subgroup. Methods： The sample of patients with CLL were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 1 lq22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p- were retrospectively collected and analyzed. Results： The overall response rate （ORR） in patients with a 17p- was 56.9%, and patients with a high percentage of 17p- （defined as more than 25% of cells harbouring a 17p-） had a lower ORR. The median overall survival （OS） in patients with a 17p- was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality （median 162.0 months, P〈0.001）. Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase （LDH）, B symptoms, unmutated IGHVand a high percentage of 17p-. Conclusions： These results indicated that patients with a 17p- CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.